Description

ACCORD BORTEZOMIB 3.5
(Bortezomib Powder for Solution for Injection 3.5 mg/Vial)

• Name and strength of active ingredient
Bortezomib 3.5 mg/Vial

• Product Description
ACCORD BORTEZOMIB 3.5: A white to off-white cake or powder in a clear glass vial. The reconstituted solution is clear and
colourless.

• Pharmacodynamics & Pharmacokinetics

Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents, other antineoplastic agents,

ATC code: L01XX32.

Mechanism of action
Bortezomib is a proteasome inhibitor. It is specifically designed to inhibit the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the turnover of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis and affects multiple signalling cascades within the cell, ultimately resulting in cancer cell death.